David Meline Joins Moderna as Chief Financial Officer
June 04 2020 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that David Meline has joined Moderna as
Chief Financial Officer, effective Monday, June 8, 2020. He will
serve on Moderna’s Executive Committee and report to Chief
Executive Officer Stéphane Bancel.
“I am pleased to welcome David to Moderna as our Chief Financial
Officer and to the Executive Committee. As we prepare for the Phase
3 studies of our SARS-CoV-2 vaccine and our CMV vaccine, we are
entering another critical phase for the Company. We have started to
build commercial capabilities and started to set up commercial
subsidiaries in several countries,” said Stéphane Bancel, Chief
Executive Officer of Moderna. “David’s global biopharmaceutical
industry and commercial experience along with his track record as
CFO of Amgen for the last 6 years and before that, as CFO of 3M,
make him a great addition to our team. I look forward to partnering
with David to grow Moderna to a global enterprise focused on
development and delivery of novel therapeutics and vaccines.”
Mr. Meline joins Moderna from Amgen (Nasdaq: AMGN), where he
served as Chief Financial Officer and EVP from 2014 through 2019.
At Amgen, he was responsible for all finance, information systems
and global business services activities across 100 countries. In
this role, Mr. Meline led enterprise-wide transformation while
increasing growth and productivity and reducing development cycle
time. Prior to Amgen, Mr. Meline spent six years at 3M Company
(NYSE: MMM), where he most recently served as CFO and Senior Vice
President and was responsible for all 3M financial activities
across 70 countries of operation. Previously, Mr. Meline held
numerous leadership positions at General Motors, including Vice
President and CFO for GM North America. During his tenure at GM,
Mr. Meline lived and worked on five continents.
“With its impressive mRNA platform demonstrating promise across
multiple diseases, Moderna is in a unique position to accelerate
its business development and entry to markets around the world,”
said Mr. Meline. “I look forward to joining the Moderna team to
help the company enter this new phase of growth and assist the full
build out of its business model, including positive impact on large
populations and entry into new geographies.”
Mr. Meline received his Master of Business Administration in
finance from the University of Chicago, his Master of Science in
economics from the London School of Economics and his Bachelor of
Science in mechanical engineering from Iowa State University.
In Moderna’s May 7th quarterly press release, Dr. Lorence Kim,
Moderna’s current CFO, announced plans to depart from Moderna in
August 2020, after six years of service. Dr. Kim will continue to
report to Mr. Bancel until his departure in August as he helps to
ensure a smooth transition of the CFO role to Mr. Meline.
“As we begin the transition of the CFO role, I would again like
to thank Lorence for his tremendous impact on Moderna’s success
over the last six years,” Mr. Bancel said. “Lorence brought unique
skills and made vital contributions in helping to build Moderna
from a private pre-clinical development stage company to a public
late development stage company. I have enjoyed having him as my
partner.”
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and
autoimmune and inflammatory diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and the Biomedical Advanced Research and Development
Authority (BARDA), a division of the Office of the
Assistant Secretary for Preparedness and Response (ASPR) within
the U.S. Department of Health and Human Services (HHS). Moderna
has been named a top biopharmaceutical employer by Science for the
past five years. To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200604005219/en/
Moderna Media: Colleen Hussey Senior Manager, Corporate
Communications 203-470-5620 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024